Passage Bio (PASG)
(Delayed Data from NSDQ)
$1.32 USD
+0.10 (8.20%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.32 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth F Momentum D VGM
Brokerage Reports
0 items in cart
Passage Bio, Inc. [PASG]
Reports for Purchase
Showing records 21 - 40 ( 43 total )
Company: Passage Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Passage Bio, Inc.
Industry: Medical - Biomedical and Genetics
After 1Q22 Update, Looking Ahead to GM1 Update Later This Week
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Passage Bio, Inc.
Industry: Medical - Biomedical and Genetics
Shuffling Things Around - PASG Announces Strategic Shifts,R&D Departure
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Passage Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Passage Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Passage Bio, Inc.
Industry: Medical - Biomedical and Genetics
PBGM01 Continues to Demonstrate Encouraging Signs;Dosing Continuing
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Passage Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Passage Bio, Inc.
Industry: Medical - Biomedical and Genetics
IMAGINE-ing Big Things for PBGM01 - Preliminary Biomarker Data Arrives
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Passage Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Passage Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Passage Bio, Inc.
Industry: Medical - Biomedical and Genetics
GM1 Readout On Track For 4Q21; More Catalysts To Come
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Passage Bio, Inc.
Industry: Medical - Biomedical and Genetics
Management Moves an Unexpected Twist, But Makes Sense
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Passage Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Passage Bio, Inc.
Industry: Medical - Biomedical and Genetics
Front Of Mind - Key Highlights from FTD Focus Event
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Passage Bio, Inc.
Industry: Medical - Biomedical and Genetics
COVID Headwinds Still Need To Be Dealt With For PBGM01
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Passage Bio, Inc.
Industry: Medical - Biomedical and Genetics
Imagine That - First GM1 Patient Dosed, Data On Track For Mid-2021
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Passage Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Passage Bio, Inc.
Industry: Medical - Biomedical and Genetics
Onward! PBFT02 IND Cleared By FDA - Phase 1/2 FTD Study To Begin
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Passage Bio, Inc.
Industry: Medical - Biomedical and Genetics
Inaugural Virtual R&D Event Sheds More Light on GM1 Opportunity
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L